Purinergic P2X3 receptor antagonist - Bayer/Evotec

Drug Profile

Purinergic P2X3 receptor antagonist - Bayer/Evotec

Alternative Names: Endometriosis/P2X3 antagonist - Bayer/Evotec

Latest Information Update: 08 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare; Evotec AG
  • Developer Evotec AG
  • Class
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Endometriosis

Most Recent Events

  • 04 Aug 2016 Phase-I clinical trials in Endometriosis in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top